DiaSorin to Acquire Siemens' ELISA Immunodiagnostics Business
By LabMedica International staff writers Posted on 01 Aug 2017 |
DiaSorin S.p.A. (Saluggia, Italy) has entered into an agreement to acquire Siemens Healthineers’ (Erlangen, Germany) micro-titre-based ELISA immunodiagnostic business portfolio and related tangible and intangible assets, including customer sales and distribution contracts, installed base of instruments and relevant intellectual property.
DiaSorin develops, produces and markets reagent kits for IVD worldwide, and offers a broad range of specialty tests in the immunodiagnostics market and new tests in the molecular diagnostics markets. Siemens Healthineers offers a comprehensive portfolio of products and services in its core areas of diagnostic and therapeutic imaging and in laboratory diagnostics and molecular medicine. The company’s ELISA immunodiagnostic products are marketed in hospitals, private laboratories and blood banks.
DiaSorin will acquire the ELISA immunodiagnostic business portfolio and relevant assets from Siemens Healthineers, excluding the transfer of employees or manufacturing facility and capability, on a debt-free cash-free basis for a total consideration of up to Euro 47.5 million.
Siemens Healthineers will continue to manufacture and provide its ELISA immunodiagnostic reagent kits exclusively to DiaSorin for up to three years, enabling continuous supply of its current ELISA immunodiagnostic products to customers.
The acquisition is in line with DiaSorin’s strategy to convert customers using ELISA products to its CLIA platforms and products solution, leveraging on the completeness of its CLIA menu and the features of its LIAISON platforms. Siemens Healthineers’ ELISA immunodiagnostic business portfolio will allow DiaSorin to access a significant customer base, mostly in Europe, thus providing it with the opportunity to further expand its global commercial presence to create new business opportunities for the promotion and marketing of its CLIA products.
“We are very excited to acquire the Siemens Healthineers ELISA business,” said Carlo Rosa, CEO of DiaSorin Group. “We think this deal would perfectly fit with our long-term strategy aimed at expanding our customer base leveraging on our extensive CLIA specialties menu and LIAISON Platforms.”
DiaSorin develops, produces and markets reagent kits for IVD worldwide, and offers a broad range of specialty tests in the immunodiagnostics market and new tests in the molecular diagnostics markets. Siemens Healthineers offers a comprehensive portfolio of products and services in its core areas of diagnostic and therapeutic imaging and in laboratory diagnostics and molecular medicine. The company’s ELISA immunodiagnostic products are marketed in hospitals, private laboratories and blood banks.
DiaSorin will acquire the ELISA immunodiagnostic business portfolio and relevant assets from Siemens Healthineers, excluding the transfer of employees or manufacturing facility and capability, on a debt-free cash-free basis for a total consideration of up to Euro 47.5 million.
Siemens Healthineers will continue to manufacture and provide its ELISA immunodiagnostic reagent kits exclusively to DiaSorin for up to three years, enabling continuous supply of its current ELISA immunodiagnostic products to customers.
The acquisition is in line with DiaSorin’s strategy to convert customers using ELISA products to its CLIA platforms and products solution, leveraging on the completeness of its CLIA menu and the features of its LIAISON platforms. Siemens Healthineers’ ELISA immunodiagnostic business portfolio will allow DiaSorin to access a significant customer base, mostly in Europe, thus providing it with the opportunity to further expand its global commercial presence to create new business opportunities for the promotion and marketing of its CLIA products.
“We are very excited to acquire the Siemens Healthineers ELISA business,” said Carlo Rosa, CEO of DiaSorin Group. “We think this deal would perfectly fit with our long-term strategy aimed at expanding our customer base leveraging on our extensive CLIA specialties menu and LIAISON Platforms.”
Latest Industry News
- Thermo Fisher and Bio-Techne Enter Into Strategic Distribution Agreement for Europe
- ECCMID Congress Name Changes to ESCMID Global
- Bosch and Randox Partner to Make Strategic Investment in Vivalytic Analysis Platform
- Siemens to Close Fast Track Diagnostics Business
- Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics
- Sysmex and Hitachi Collaborate on Development of New Genetic Testing Systems
- Sysmex and CellaVision Expand Collaboration to Advance Hematology Solutions
- BD and Techcyte Collaborate on AI-Based Digital Cervical Cytology System for Pap Testing
- Medlab Middle East 2024 to Address Transformative Potential of Artificial Intelligence
- Seegene and Microsoft Collaborate to Realize a World Free from All Diseases and Future Pandemics
- Medlab Middle East 2024 to Highlight Importance of Sustainability in Laboratories
- Fujirebio and Agappe Collaborate on CLIA-Based Immunoassay
- Medlab Middle East 2024 to Highlight Groundbreaking NextGen Medicine
- bioMérieux Acquires Software Company LUMED to Support Fight against Antimicrobial Resistance
- Roche Acquires LumiraDx's Point of Care Technology for USD 295 Million
- Bruker Acquires IVD Manufacturer ELITech Group and Cell Imaging Company Phasefocus